This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

99.12 +0.58 (+0.59%)
Streaming Delayed Price Updated: 1:53 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
46 Biggest Movers From Yesterday ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
Via Talk Markets
Topics Stocks
News headline image
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
News headline image
Where Protagonist Therapeutics Stands With Analysts ↗
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals ↗
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
28 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical... 
Via Benzinga
News headline image
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today ↗
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. 
Via InvestorPlace
News headline image
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug ↗
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies. 
Via Investor's Business Daily
News headline image
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program ↗
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
News headline image
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy ↗
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. 
Via InvestorPlace
News headline image
58 Biggest Movers From Yesterday ↗
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
News headline image
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
20 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
News headline image
32 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
News headline image
Why Protagonist Therapeutics Stock Plunged Today ↗
The FDA has placed a clinical hold on testing of rusfertide. 
Via The Motley Fool
News headline image
Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge ↗
Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3.... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
Protagonist Therapeutics (NASDAQ:PTGX) has observed the following analyst ... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher ↗
Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B ↗
Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 ↗
Upgrades For Methanex Corp (NASDAQ: 
Via Benzinga
News headline image
48 Biggest Movers From Friday ↗
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
News headline image
PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% Today ↗
Today, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.